CeriBell (NASDAQ:CBLL – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($1.85) EPS for the quarter, missing the consensus estimate of ($0.82) by ($1.03), Zacks reports. The business had revenue of $17.20 million for the quarter, compared to analysts’ expectations of $17.06 million.
CeriBell Stock Performance
Shares of CBLL stock traded up $0.43 during trading on Thursday, reaching $28.31. 29,546 shares of the company’s stock traded hands, compared to its average volume of 228,231. CeriBell has a 1 year low of $23.00 and a 1 year high of $29.53.
Wall Street Analyst Weigh In
A number of analysts recently commented on CBLL shares. TD Cowen began coverage on CeriBell in a report on Tuesday, November 5th. They set a “buy” rating and a $31.00 price target on the stock. Canaccord Genuity Group initiated coverage on CeriBell in a research note on Tuesday, November 5th. They set a “buy” rating and a $30.00 target price on the stock. JPMorgan Chase & Co. initiated coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set an “overweight” rating and a $32.00 price target for the company. Canaccord Genuity Group lifted their price objective on shares of CeriBell from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, William Blair started coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set an “outperform” rating for the company. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $31.20.
About CeriBell
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Recommended Stories
- Five stocks we like better than CeriBell
- Insider Trades May Not Tell You What You Think
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- Trading Halts Explained
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
